Literature DB >> 3260942

Human interleukin-2 activated cytotoxic cells kill autologous glioma cells in vitro.

V Bosnes1, H Hirschberg.   

Abstract

We have cultured peripheral blood lymphocytes (PBL) from glioblastoma patients in recombinant interleukin-2 (IL-2) containing medium for a period of 5 days. The cytotoxicity of these cells was tested on 51Cr-labelled autologous dissociated glioblastoma cells which had not been cultured. Significant cytotoxicity against glioma cells was observed in seven out of nine cases. IL-2 activated PBL from normal donors were equally cytotoxic against these glioma cells. Autologous lymphocytes activated by phytohaemagglutinin were also lysed in most cases, and the erythroleukemia cell line K562 was highly susceptible to the cytotoxic capability of the IL-2 activated PBL. In cold target inhibition experiments, K562 inhibited the cytotoxicity against both autologous and allogenic glioma cells, and glioma cells inhibited the cytotoxicity against K562. Following immunomagnetic separation, the IL-2 activated cells demonstrated cytotoxicity against glioma cells, K562 cells, and PHA blasts in both the CD8+ and the CD8- subsets.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260942     DOI: 10.1007/bf00163545

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

1.  Cell mediated lympholysis: CML. a microplate technique requiring few target cells and employing a new method of supernatant collection.

Authors:  H Hirschberg; H Skare; E Thorsby
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

Review 2.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

3.  Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.

Authors:  A A Rayner; E A Grimm; M T Lotze; D J Wilson; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

4.  The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.

Authors:  E A Grimm; D J Wilson
Journal:  Cell Immunol       Date:  1985-09       Impact factor: 4.868

5.  Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Authors:  L M Muul; E P Director; C L Hyatt; S A Rosenberg
Journal:  J Immunol Methods       Date:  1986-04-17       Impact factor: 2.303

6.  Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.

Authors:  S Miyatake; H Handa; J Yamashita; T Yamasaki; M Ueda; Y Namba; M Hanaoka
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

7.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

8.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.